Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-04-08
2008-09-23
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S472000, C540S567000
Reexamination Certificate
active
07427613
ABSTRACT:
The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.
REFERENCES:
patent: 2006/0223795 (2006-10-01), Bezencon et al.
patent: 2007/0111989 (2007-05-01), Bezencon et al.
patent: WO 92/05174 (1992-04-01), None
patent: WO 97/09311 (1997-03-01), None
patent: WO 98/39328 (1998-09-01), None
U.S. Appl. No. 10/575,794, filed Apr. 2006, Benzecon et al.
U.S. Appl. No. 10/581,824, filed Jun. 2006, Benzecon et al.
Chawla et. al.; CRIPS vol. 5, No. 1, p. 9-12.
Newman et. al.; DDT vol. 8, No. 19, p. 898-905.
Vippagunta, et. al., Advanced Drug Delivery Reviews; 48, (2001) 3-26.
B.K. Blount et al., J. Chem. Soc., pp. 2485-2487 (1932).
Neale et al., J. Org. Chem., vol. 30, pp. 3683-3688 (1965).
Brabander et al., J. Org. Chem., pp. 4053-4055 (1967).
Dallacker et al., Chem. Ber., vol. 104, pp. 2517-2525 (1971).
Jacques et al., Tetrahedron, vol. 33, pp. 581-588 (1977).
Meyers et al., J. Am. Chem. Soc., vol. 104, pp. 877-879 (1982).
Jerry March, “Reactions, Mechanisms, and Structure”, Advanced Organic Chemistry, published by John Wiley & Sons (1929).
Kihara et al., Heterocycles, vol. 29, pp. 957-965 (1989).
Glover et al., Tetrahedron, vol. 46, pp. 7247-7262 (1990).
Fuji et al., Tetrahedron Letters, vol. 31, pp. 6553-6556 (1990).
Ishihara et al., Chem. Pharm. Bull., vol. 39, pp. 3225-3235 (1991).
Neutel, M.D. et al., American Heart Journal, vol. 122, pp. 1094-1100 (1991).
Zhuangyu et al., Synthesis, pp. 539-542 (1991).
Israili, Ph.D. et al., Annals of Internal Medicine, vol. 117, pp. 234-242 (1992).
Pfeffer, M.D, Ph.D., et al., The New England Journal of Medicine, vol. 327, No. 10, pp. 669-677 (1992).
Michael A. Weber et al., American Journal of Hypertension, Inc., vol. 5, pp. 247S-251S (1992).
Qi-dong et al., Chemical Research in Chinese Universities, vol. 8, No. 4, pp. 468-472 (1992).
Ahsan Husain, Journal of Hypertension, vol. 11, pp. 1155-1159 (1993).
Dale O. Kiesewetter et al., Tetrahedron:Asymmetry, vol. 4, pp. 2183-2198 (1993).
Aziz et al., Journal of Hypertension, vol. 12, pp. 419-427 (1994).
Breyer et al., Kidney International, vol. 45—Supplemental 45, pp. S156-S160 (1994).
Rosenberg et al., Kidney International, vol. 45, pp. 403-410 (1994).
Vaughan et al., Cardiovascular Research, vol. 28, pp. 159-165 (1994).
Hollis D. Kleinert, Cardiovascular Drugs and Theraphy, vol. 9, pp. 645-655 (1995).
Lavastre et al., Bull. Soc. Chim. Fr., vol. 132, pp. 188-195 (1995).
Majewski et al., J. Org. Chem., vol. 60, pp. 5825-5830 (1995).
Waeber et al., Handbook of Hypertension, vol. 8: Pathiophysiology of Hypertension—Regulatory Mechanisms, pp. 489-519 (1986).
Ho et al., Tetrahedron Letters, vol. 38, pp. 2799-2802 (1997).
Smith et al., J. Med. Chem., vol. 41, pp. 787-797 (1998).
Oefner et al., Chemistry & Biology, vol. 6, pp. 127-131 (1999).
Vieira et al., Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1397-1402 (1999).
Bellier et al., J. Med. Chem., vol. 43, pp. 3614-3623 (2000).
Loeppky et al., J. Org. Chem., vol. 65, pp. 96-103 (2000).
Morita et al., Heterocycles, vol. 52, pp. 1163-1169 (2000).
Rahuel et al., Chemistry & Biology, vol. 7, pp. 493-504 (2000).
Blass et al., Tetrahedron Letters, vol. 42, pp. 1611-1613 (2001).
Marki et al., II Farmaco, vol. 56, pp. 21-27 (2001).
Aliskiren Fumarate, Drugs of the Future, vol. 26, pp. 1139-1148 (2001).
Melnyk et al., J. Org. Chem., vol. 66, pp. 4153-4160 (2001).
Ross et al., J. Org. Chem., vol. 31, pp. 133-137 (1966).
Fouad-Tarazi, M.D. et al., The American Journal of Medicine, vol. 84—Supplemental 3A, pp. 83-86 (1988).
Cossy et al., Tetrahedron Letters, vol. 41, pp. 2097-2099 (2000).
Bezencon Olivier
Bur Daniel
Fischli Walter
Remen Lubos
Richard-Bildstein Sylvia
Actelion Pharmaceuticals Ltd.
Dickstein & Shapiro LLP
Murray Jeffrey H
Wilson James O.
LandOfFree
7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989342